Cochlear (ASX:COH) has been assigned a $53.00 price target by equities researchers at Jefferies Financial Group in a research report issued on Thursday. The brokerage currently has a “buy” rating on the stock.
Shares of COH stock traded down A$3.70 ($2.62) during trading hours on Thursday, hitting A$166.03 ($117.75). The company’s stock had a trading volume of 275,815 shares, compared to its average volume of 194,422. Cochlear has a twelve month low of A$129.18 ($91.62) and a twelve month high of A$192.80 ($136.74). The company has a current ratio of 2.03, a quick ratio of 1.35 and a debt-to-equity ratio of 24.18.
In other news, insider Dig Howitt sold 5,000 shares of the firm’s stock in a transaction on Friday, November 9th. The shares were sold at an average price of A$175.23 ($124.28), for a total value of A$876,150.00 ($621,382.98).
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories.
Recommended Story: Marijuana Stocks Future Looks Bright
Receive News & Ratings for Cochlear Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cochlear and related companies with MarketBeat.com's FREE daily email newsletter.